ISG Technologies changes name to Cedara
ISG Technologies changes name to CedaraPACS and image-guided surgery firm ISG Technologies has changed its name. Now called Cedara Software, the Mississauga, ON-based firm has embarked on a worldwide corporate branding campaign intended to
ISG Technologies changes name to Cedara
PACS and image-guided surgery firm ISG Technologies has changed its name. Now called Cedara Software, the Mississauga, ON-based firm has embarked on a worldwide corporate branding campaign intended to highlight the companys healthcare software products and services. The name change and the companys new stock trading symbols are contingent on shareholder approval. Until they receive approval, the firm will continue to trade under ISO (Toronto Stock Exchange) and ISGTF (Nasdaq).
Cedara will be divided into three core businesses: software and service, image management, and image-guided therapy. Two of the three businesses have gained new executive leadership in the past year. The company named Arun Menawat to the post of general manager/president of the software and service division, which develops the companys Image Application Platform software, designed for 3-D post-processing, CT, digital x-ray, MRI, mammography, nuclear medicine, and ultrasound equipment. Cedara has also appointed Alyn Ford to the position of general manager/vice president of its image management business, which develops software products that display, analyze, and store medical images (PNN 6/99).
- Search again
- Homepage
GE HealthCare Debuts AI-Powered Cardiac CT Device at ACC Conference
April 1st 2025Featuring enhanced low-dose image quality with motion-free images, the Revolution Vibe CT system reportedly facilitates improved diagnostic clarity for patients with conditions ranging from in-stent restenosis to atrial fibrillation.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
